MX2017003138A - Compuestos de azetidiniloxifenilpirrolidina. - Google Patents

Compuestos de azetidiniloxifenilpirrolidina.

Info

Publication number
MX2017003138A
MX2017003138A MX2017003138A MX2017003138A MX2017003138A MX 2017003138 A MX2017003138 A MX 2017003138A MX 2017003138 A MX2017003138 A MX 2017003138A MX 2017003138 A MX2017003138 A MX 2017003138A MX 2017003138 A MX2017003138 A MX 2017003138A
Authority
MX
Mexico
Prior art keywords
compounds
formula
azetidinyloxyphenylpyrrolidine
azetidinyloxyphenylpyrrolidine compounds
compound
Prior art date
Application number
MX2017003138A
Other languages
English (en)
Inventor
G Deng Gary
Huang Danwen
Darshini Jesudason Cynthia
O Odingo Joshua
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54140711&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017003138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017003138A publication Critical patent/MX2017003138A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Abstract

La invención proporciona determinados compuestos de azetidiniloxifenilpirrolidina, particularmente compuestos de la fórmula I y composiciones farmacéuticas de estos. La invención proporciona además métodos para usar un compuesto de la fórmula I para tratar la vejiga hiperactiva. (ver Fórmula).
MX2017003138A 2014-09-12 2015-09-03 Compuestos de azetidiniloxifenilpirrolidina. MX2017003138A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049485P 2014-09-12 2014-09-12
PCT/US2015/048267 WO2016040083A1 (en) 2014-09-12 2015-09-03 Azetidinyloxyphenylpyrrolidine compounds

Publications (1)

Publication Number Publication Date
MX2017003138A true MX2017003138A (es) 2017-05-23

Family

ID=54140711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003138A MX2017003138A (es) 2014-09-12 2015-09-03 Compuestos de azetidiniloxifenilpirrolidina.

Country Status (34)

Country Link
US (2) US10781202B2 (es)
EP (1) EP3191466B1 (es)
JP (1) JP6285610B2 (es)
KR (1) KR101857931B1 (es)
CN (1) CN106795137B (es)
AP (1) AP2017009778A0 (es)
AR (1) AR101696A1 (es)
AU (1) AU2015315533B2 (es)
BR (1) BR112017002852A2 (es)
CA (1) CA2955634A1 (es)
CL (1) CL2017000484A1 (es)
CO (1) CO2017001389A2 (es)
CR (1) CR20170050A (es)
DK (1) DK3191466T3 (es)
EA (1) EA030034B1 (es)
EC (1) ECSP17014972A (es)
ES (1) ES2770047T3 (es)
HR (1) HRP20200119T1 (es)
HU (1) HUE047551T2 (es)
IL (1) IL250378A0 (es)
LT (1) LT3191466T (es)
MX (1) MX2017003138A (es)
NZ (1) NZ729087A (es)
PE (1) PE20170328A1 (es)
PH (1) PH12017500459A1 (es)
PL (1) PL3191466T3 (es)
PT (1) PT3191466T (es)
RS (1) RS59845B1 (es)
SG (1) SG11201701225YA (es)
SI (1) SI3191466T1 (es)
TN (1) TN2017000047A1 (es)
TW (1) TW201625591A (es)
WO (1) WO2016040083A1 (es)
ZA (1) ZA201700555B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
KR20210093320A (ko) * 2018-12-18 2021-07-27 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 페닐피롤리딘계 화합물 및 그의 용도
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN112409333A (zh) * 2019-08-23 2021-02-26 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物
KR20240004495A (ko) 2021-04-29 2024-01-11 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 이소퀴놀론 화합물과 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
MXPA03006886A (es) * 2001-01-31 2003-11-13 Pfizer Prod Inc Derivados amida de acido tiazolilico, oxazolilico, pirrolilico e imidazolilico utiles como inhibidores de las isozimas pde4.
BRPI0616633A2 (pt) 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol

Also Published As

Publication number Publication date
US20170240532A1 (en) 2017-08-24
SG11201701225YA (en) 2017-03-30
AP2017009778A0 (en) 2017-03-31
NZ729087A (en) 2018-07-27
LT3191466T (lt) 2020-02-25
JP6285610B2 (ja) 2018-02-28
HUE047551T2 (hu) 2020-04-28
EP3191466A1 (en) 2017-07-19
SI3191466T1 (sl) 2020-02-28
ECSP17014972A (es) 2018-03-31
RS59845B1 (sr) 2020-02-28
PT3191466T (pt) 2020-02-17
KR20170040803A (ko) 2017-04-13
JP2017527587A (ja) 2017-09-21
TN2017000047A1 (en) 2018-07-04
KR101857931B1 (ko) 2018-05-14
AU2015315533A1 (en) 2017-02-23
PL3191466T3 (pl) 2020-05-18
CN106795137B (zh) 2020-08-25
US10781202B2 (en) 2020-09-22
CA2955634A1 (en) 2016-03-17
AR101696A1 (es) 2017-01-04
EA030034B1 (ru) 2018-06-29
IL250378A0 (en) 2017-03-30
TW201625591A (zh) 2016-07-16
EA201790156A1 (ru) 2017-06-30
AU2015315533B2 (en) 2018-03-15
PE20170328A1 (es) 2017-04-19
ES2770047T3 (es) 2020-06-30
CR20170050A (es) 2017-04-25
WO2016040083A1 (en) 2016-03-17
BR112017002852A2 (pt) 2017-12-26
CO2017001389A2 (es) 2017-05-10
PH12017500459A1 (en) 2017-07-31
ZA201700555B (en) 2018-12-19
CL2017000484A1 (es) 2017-11-10
EP3191466B1 (en) 2019-12-04
DK3191466T3 (da) 2020-01-20
US20200002318A1 (en) 2020-01-02
CN106795137A (zh) 2017-05-31
HRP20200119T1 (hr) 2020-04-03

Similar Documents

Publication Publication Date Title
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
MX2017008442A (es) Uso de picolinamidas como fungicidas.
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
AU2014375265A1 (en) Novel pyrazolyl-heteroarylamides as pesticides
TW201613853A (en) Synthesis of polycyclic-carbamoylpyridone compounds
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2017007188A (es) Compuesto antimicotico.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EP3169686A4 (en) Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX2016015298A (es) Inhibidores de nampt y metodos.
IN2014MU00859A (es)
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
DOP2017000036A (es) Compuestos de azetidiniloxifenilpirrolidina